Skip to main content
. 2006 Jun 6;103(24):9166–9171. doi: 10.1073/pnas.0600240103

Fig. 2.

Fig. 2.

Soluble IL-15Rα augments IL-15-mediated donor lymphocyte proliferation in vivo. (A) CFSE-labeled T cells were transferred i.v. into C57BL/6 (B6) recipients. On days 1 and 2 after transfer, the recipients were given i.p. injections of PBS, sIL-15Rα-Fc alone (7 μg), IL-15 alone (1.5 μg), or sIL-15Rα-Fc plus IL-15 (7 μg and 1.5 μg, respectively, which represents a 1:2 molar ratio). CFSE dilution of the donor cells was measured in spleen on day 4. Representative data for gated MP CD8+ cells are shown. (B) As in A except that the cells transferred were from lymphocytic choriomeningitis virus-immune mice (Upper) versus normal mice (Lower). (C) CFSE-labeled MP CD8+ T cells were transferred to normal B6 hosts; one day later, the hosts were injected with the indicated dose of IL-15 with or without sIL-15Rα-Fc; the dose of sIL-15Rα-Fc varied such that a 2:1 molar ratio of IL-15 to sIL-15Rα-Fc was injected. CFSE profiles for donor MP CD8+ cells in spleen at 2 days after injection are shown. (D) Compilation of data from C. For A–C, data shown are representative of two mice per group and are also representative of two independent experiments.